Originally published February 13 2006
New study emphasizes the role genes play in determining the efficacy of painkillers
by Mike Adams, the Health Ranger, NaturalNews Editor
According to a study published in Gastroenterology, genetic variation influences the effectiveness of painkillers in relieving pain and inflammation, and genetics also determines the number and severity of side effects a person may experience while taking a drug.
A study published in the January issue of the American Gastroenterological Association (AGA) journal Gastroenterology found a difference in how people responded to popular painkillers and that up to 30 percent of this variability can be attributed to an individual's genetic make-up.
This variation can influence both how useful the drugs are in affording relief from pain and inflammation, and the number and severity of the adverse effects.
This evaluation is perhaps the most rigorous look at how people vary in their response to drugs and was designed as part of a strategy to determine genetic and other markers that might help predict response and safety of these drugs, including susceptibility to cardiovascular complications.
During the past two years, evidence has emerged that COX-2s confer a risk of heart attack and stroke, resulting in two of the drugs in this class being withdrawn from the market and a black box warning being issued for a third drug.
The problems with COX-2 inhibitors were real, but involved less than 2 percent of patients who were taking them," said Garret A. FitzGerald, MD, study author from the University of Pennsylvania School of Medicine.
"Because we often underestimate just how much people differ in their response to the same dose of the same drug, there is a need to develop diagnostic methods to identify those patients at an increased risk of cardiovascular events and explore this variability in drug response to move toward an individualized approach in drug development."
Researchers at the University of Pennsylvania examined the variability, both within and between subjects, in response to celecoxib and rofecoxib, in a randomized, double-blind, placebo controlled study.
Gastroenterology, the official journal of the AGA, is the most prominent journal in the subspecialty and is in the top one percent of indexed medical journals internationally.
All content posted on this site is commentary or opinion and is protected under Free Speech. Truth Publishing LLC takes sole responsibility for all content. Truth Publishing sells no hard products and earns no money from the recommendation of products. NaturalNews.com is presented for educational and commentary purposes only and should not be construed as professional advice from any licensed practitioner. Truth Publishing assumes no responsibility for the use or misuse of this material. For the full terms of usage of this material, visit www.NaturalNews.com/terms.shtml